CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.97: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.82%
Annual Rate
CNY 0.36Paid semi-annual
Payout Ratio
25.8%Sustainable
Payback Period
71.9 yr
Last Ex-Dividend
Jul 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.83BCNY867.46M · vs all stocks (USD)
Trailing P/E
27.82xRevenue (TTM)
1.49BCNY221.96M · vs all stocks (USD)
Profit Margin
15.00%Beta
0.1750xvs all stocks
52-Week Change
-13.27%vs all stocks
Forward Annual Dividend Yield
0.82%vs all stocks
Market Capitalization
5.83BCNY867.46M · vs all stocks (USD)
Enterprise Value
6.11BCNY907.99M · vs all stocks (USD)
Trailing P/E
27.82xForward P/E
29.10xPrice to Sales (TTM)
4.13xPrice to Book (MRQ)
2.92xEnterprise to Revenue
4.09xEnterprise to EBITDA
27.67xGross Margin
57.28%Profit Margin
15.00%Operating Margin
11.68%Return on Assets (TTM)
3.27%Return on Equity (TTM)
11.02%Revenue (TTM)
1.49BCNY221.96M · vs all stocks (USD)
Revenue per Share (TTM)
11.31CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-3.50%Gross Profit (TTM)
880.11MCNY130.88M · vs all stocks (USD)
EBITDA (TTM)
234.04MCNY34.80M · vs all stocks (USD)
Net Income (TTM)
223.94MCNY33.30M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-34.80%Operating Cash Flow (TTM)
331.74MCNY49.33M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-167.53MCNY-24.91M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3576CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
0.82%vs all stocks
Trailing Annual Dividend Rate
0.6074CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.39%vs all stocks
Payout Ratio
25.82%Revenue
1.50BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
597.40MCNYFY2025 · Dec 31, 2025Gross Profit
906.83MCNYFY2025 · Dec 31, 2025Operating Income
165.64MCNY24.63M · vs all stocks (USD)
Pre-tax Income
240.90MCNYFY2025 · Dec 31, 2025Income Tax Expense
12.80MCNYFY2025 · Dec 31, 2025Net Income
228.10MCNYFY2025 · Dec 31, 2025EBIT
241.54MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
322.29MCNYFY2025 · Dec 31, 2025Research & Development
129.85MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
523.43MCNYFY2025 · Dec 31, 2025Other Operating Expenses
14.94MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
647.37KCNYFY2025 · Dec 31, 2025EPS (Basic)
1.81CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.77CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
131.65MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
131.65MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
228.10MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.18MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
191.50MCNYFY2025 · Dec 31, 2025Free Cash Flow
-328.74MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
201.48MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
228.10MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.42MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-56.44MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.43MCNYFY2025 · Dec 31, 2025Capital Expenditures
-520.24MCNYFY2025 · Dec 31, 2025Net Acquisitions
5.97MCNYFY2025 · Dec 31, 2025Purchase of Investments
-733.47MCNYFY2025 · Dec 31, 2025Sale of Investments
645.14MCNYFY2025 · Dec 31, 2025Other Investing Activity
-6.56MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-609.17MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
384.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-62.96MCNYFY2025 · Dec 31, 2025Other Financing Charges
14.97MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
336.01MCNYFY2025 · Dec 31, 2025Shares Outstanding
131.32MSharesUpdated Aug 21, 2026Float Shares
57.59MSharesUpdated Aug 21, 2026% Held by Insiders
57.92%vs all stocks
% Held by Institutions
6.16%vs all stocks
Total Cash (MRQ)
208.26MCNY30.97M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.59CNYUpdated Aug 21, 2026Total Debt (MRQ)
672.52MCNY100.01M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3240xCurrent Ratio (MRQ)
2.83xBook Value per Share (MRQ)
15.81CNYUpdated Aug 21, 2026Total Assets
3.05BCNY454.11M · vs all stocks (USD)
Total Current Assets
1.18BCNYFY2025 · Dec 31, 2025Total Liabilities
1.01BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.88BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
600.26MCNYFY2025 · Dec 31, 2025Total Current Liabilities
410.70MCNYFY2025 · Dec 31, 2025Cash
201.48MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.30MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
203.78MCNYFY2025 · Dec 31, 2025Other Short-term Investments
10.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
210.38MCNYFY2025 · Dec 31, 2025Inventory
392.46MCNYFY2025 · Dec 31, 2025Accounts Payable
181.53MCNYFY2025 · Dec 31, 2025Short-term Debt
371.00KCNYFY2025 · Dec 31, 2025Other Current Liabilities
21.05MCNYFY2025 · Dec 31, 2025Long-term Debt
497.60MCNYFY2025 · Dec 31, 2025Common Stock (Book)
131.32MCNYFY2025 · Dec 31, 2025Retained Earnings
990.46MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.04BCNY303.77M · vs all stocks (USD)
52-Week Low
40.33CNYUpdated Aug 21, 202652-Week High
66.88CNYUpdated Aug 21, 202652-Week Change
-13.27%vs all stocks
Beta
0.1750xvs all stocks
50-Day MA
47.40CNYUpdated Aug 21, 2026200-Day MA
49.63CNYUpdated Aug 21, 2026Avg 10-Day Volume
3.49MSharesUpdated Aug 21, 2026Avg 30-Day Volume
3.95MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.66CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.97: safe zoneNotable
Altman Z-Score: 4.97
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow